Caris Chromoseq data collection for AML, MDS, and MPN

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects clinical data from patients who undergo the Caris Chromoseq assay for hematologic malignancies. It aims to compare Chromoseq’s risk stratification, ease of use, and turnaround time against conventional cytogenetics, FISH, and NGS. Participants must be adults with AML, MDS, or MPN and have Chromoseq ordered by their physician, alongside standard genomic testing. Data collection focuses on real-world use in a single sponsor site, Caris Life Sciences in Phoenix, AZ.

Why it matters

Who can join: the full rules

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study and has signed consent form
2. Subject must be 18 or older
3. Subject be diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN)
4. Physician must order or plan to order Caris Chromoseq for their patient
5. Physicians must order or have ordered conventional cytogenetics, FISH, and NGS testing for AML, MDS, or MPN within the same timeframe of Caris Chromoseq without intervening line of therapy.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Patient for whom Caris Chromoseq is not being ordered
2. Patient is pregnant or lactating
3. Patient is not able or willing to provide consent to data collection for this protocol

Where it's running

• Caris Life Sciences
  Phoenix, Arizona, United States Recruiting

Study contacts

• Study coordinator: Mary Baker
• Email: carisresearch@carisls.com
• Phone: 602-571-2771

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Venetoclax TDM in newly diagnosed AML: exposure and prognosis

  This study checks if measuring venetoclax levels and adjusting treatment helps people with newly diagnosed AML who are getting VEN-AZA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou · NCT07670130

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Ziftomenib for relapsed/refractory NPM1-mutated AML in Japanese adults

  This study will test whether ziftomenib can help adults with relapsed or refractory NPM1-mutated AML who have few other options.

  Recruiting at 15 sites Phase 2 Kyowa Kirin Co., Ltd. · Chiba and 19 other locations · NCT07623616

• VABu Conditioning for elderly AML patients undergoing stem cell transplant

  This trial tests a VABu conditioning regimen to see if it helps older AML patients before allogeneic stem cell transplantation.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07583888

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.